Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes
Ella Day | July 10, 2025 | News story | Mergers and Acquisitions, Research and Development | Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases
Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting immune-mediated diseases, with an initial focus on type 1 diabetes (T1D). The collaboration aims to establish robust, scalable manufacturing processes and support clinical trial preparation.
Nimvec AM510 is designed to restore immune tolerance to insulin-producing beta cells through targeting proinsulin – the key antigen driving autoimmune destruction in T1D. By addressing this underlying cause, the therapy aims to prevent disease progression. Preclinical studies have shown that the Nimvec platform doesn’t trigger harmful immune responses, ensuring durable therapeutic effect.
Under the new agreement, Amarna will transfer and optimise its research-scale production processes for Nimvec AM510 at NorthX’s development facilities. NorthX will support the development of scalable, cGMP-compliant manufacturing and analytical processes, laying the foundations for first-in-human trials, planned for 2027.
“With this investment, we are accelerating our path to clinical trials and moving closer to providing a potential cure for T1D,” said Henk Streefkerk, CEO of Amarna Therapeutics.
“Our combined expertise will help ensure the highest standards in process development and manufacturing as we advance this promising therapy,” added Janet Hoogstraate, CEO of NorthX Biologics.
The partnership also establishes a framework for future Nimvec-based therapies in other autoimmune and chronic inflammatory conditions.
Ella Day
10/7/25
Related Content
Rare diseases – spinal muscular atrophy
Spinal muscular atrophy (SMA) is a rare disease characterised by voluntary muscle weakness that can …
Five Facts about spinal muscular atrophy
1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons …
ProteoNic Biosciences launches platform to enhance cell line productivity
ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the …
